9E9-19539-81181
3 vaccinations
3 coded responses
12 check-ins
2 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 12-15
- ZIP prefix
- 210 / MD
- Registered
- 2021-12-13
- Relationship
- Child or adolescent in my care
- Guardian
- LAA-30897-26266
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-05-13
Dose 1 — Pfizer-BioNTech
-
2021-06-03
Dose 2 — Pfizer-BioNTech
-
2021-12-13
Registered in v-safe
-
2022-01-04
Dose 3 — Pfizer-BioNTech
-
2022-01-08
Survey response — days 1–6 daily, dose 3, dependentMedDRA: Axillary pain, Pain in extremity — Feeling: GoodFree text: Has achy arm and axilla on side of shot for 24 hrs after dose 3MedDRA releases: 2024-11 · check-in free text available
- 2022-01-09
- 2022-01-10
- 2022-01-11
- 2022-01-18
- 2022-01-25
- 2022-02-01
- 2022-02-08
- 2022-02-15
- 2022-04-05
-
2022-07-05
Survey response — 6 months, dose 3, dependentMedDRA: COVID-19, SARS-CoV-2 test negative — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Had Covid 19 in April 2022 and experienced Paxlovid rebound. Total course, including about a week with no symptoms and negative rapid test after 5d of Paxlovid, lasted about 25 days. Was reported to FDA via MedWatch as a case of Paxlovid reboundMedDRA releases: 2024-11 · check-in free text available
-
2023-01-04
Survey response — 12 months, dose 3, dependentMedDRA: Attention deficit hyperactivity disorder — Feeling: Good · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11
-
2023-01-04
Report sent to call center — 12 months, dose 3, dependentGet care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · Outpatient clinic or urgent care clinic visit · 1 call case(s)
- 2023-01-05
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-05-13 | Pfizer-BioNTech | No |
| 2 | 2021-06-03 | Pfizer-BioNTech | No |
| 3 | 2022-01-04 | Pfizer-BioNTech | No |
Call center
1 call center case
1 unsuccessful
Free text
Release 10 — days 1–6 daily, dose 3, dependent
Systemic reaction (other): Has achy arm and axilla on side of shot for 24 hrs after dose 3
Release 12 — 6 months, dose 3, dependent
Symptoms: Had Covid 19 in April 2022 and experienced Paxlovid rebound. Total course, including about a week with no symptoms and negative rapid test after 5d of Paxlovid, lasted about 25 days. Was reported to FDA via MedWatch as a case of Paxlovid rebound
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Attention deficit hyperactivity disorder | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
| SRO | Axillary pain | · | · | ✓ |
| SRO | Pain in extremity | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release